{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:00Z","timestamp":1790775600568,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.canlet.2014.10.037","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T20:58:59Z","timestamp":1415134739000},"page":"819-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"PB","title":["Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer"],"prefix":"10.1016","volume":"356","author":[{"given":"Yosuke","family":"Togashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kogita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"de Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-0846","authenticated-orcid":false,"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.10.037_bib0010","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.10.037_bib0020","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.10.037_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.canlet.2014.10.037_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jso.23213","article-title":"Molecular pathways in pancreatic carcinogenesis","volume":"107","author":"Macgregor-Das","year":"2013","journal-title":"J. Surg. Oncol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","article-title":"TGFbeta signalling: a complex web in cancer progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.10.037_bib0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.canlet.2014.10.037_bib0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4161\/cc.11.4.19130","article-title":"The emerging role of the TGF\u03b2 tumor suppressor pathway in pancreatic cancer","volume":"11","author":"Birnbaum","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2014.10.037_bib0050","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1101\/gad.1475506","article-title":"Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression","volume":"20","author":"Ijichi","year":"2006","journal-title":"Genes Dev"},{"key":"10.1016\/j.canlet.2014.10.037_bib0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2007.01.017","article-title":"Kras(G12D) and Smad4\/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas","volume":"11","author":"Izeradjene","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.10.037_bib0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<860::AID-IJC11>3.0.CO;2-5","article-title":"Concomitant over-expression of activin\/inhibin beta subunits and their receptors in human pancreatic cancer","volume":"77","author":"Kleeff","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2014.10.037_bib0065","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1073\/pnas.051484398","article-title":"ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma","volume":"98","author":"Su","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2014.10.037_bib0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.stem.2011.10.001","article-title":"Nodal\/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy","volume":"9","author":"Lonardo","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2014.10.037_bib0075","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1210\/endo.140.11.7141","article-title":"Expression of activin A and follistatin core proteins by human prostate tumor cell lines","volume":"140","author":"McPherson","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2014.10.037_bib0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/jhep.2000.8535","article-title":"Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells","volume":"32","author":"Yokomuro","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2014.10.037_bib0085","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/0008-5472.CAN-04-2828","article-title":"Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms","volume":"65","author":"Panopoulou","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.037_bib0090","doi-asserted-by":"crossref","first-page":"7968","DOI":"10.1158\/0008-5472.CAN-04-3553","article-title":"Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells","volume":"65","author":"Burdette","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.037_bib0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2009.05.010","article-title":"Activin is a potent growth suppressor of epithelial ovarian cancer cells","volume":"285","author":"Ramachandran","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2014.10.037_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039381","article-title":"Effects of activin and TGF\u03b2 on p21 in colon cancer","volume":"7","author":"Bauer","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2014.10.037_bib0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1476-4598-13-126","article-title":"Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer","volume":"13","author":"Togashi","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2014.10.037_bib0110","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/bjc.2011.348","article-title":"Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer","volume":"105","author":"Kaneda","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2014.10.037_bib0115","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1349-7006.2008.00896.x","article-title":"Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU","volume":"99","author":"Yanagihara","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canlet.2014.10.037_bib0120","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1158\/0008-5472.CAN-04-2360","article-title":"Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474","volume":"64","author":"Arao","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.037_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00441-011-1201-y","article-title":"Non-Smad signaling pathways","volume":"347","author":"Mu","year":"2012","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.canlet.2014.10.037_bib0130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1535-6108(03)00308-8","article-title":"p21Waf1\/Cip1 as a therapeutic target in breast and other cancers","volume":"4","author":"Weiss","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.10.037_bib0135","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.10.037_bib0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.canlet.2014.10.037_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2044-5040-2-3","article-title":"TAK-1\/p38\/nNF\u03baB signaling inhibits myoblast differentiation by increasing levels of Activin A","volume":"2","author":"Trendelenburg","year":"2012","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.canlet.2014.10.037_bib0150","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1096\/fj.13-245894","article-title":"Elevated expression of activins promotes muscle wasting and cachexia","volume":"28","author":"Chen","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2014.10.037_bib0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tem.2009.11.009","article-title":"Inhibins: from reproductive hormones to tumor suppressors","volume":"21","author":"Stenvers","year":"2010","journal-title":"Trends Endocrinol. Metab"},{"key":"10.1016\/j.canlet.2014.10.037_bib0160","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1593\/neo.81582","article-title":"Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma","volume":"11","author":"Seder","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2014.10.037_bib0165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/JTO.0b013e31819c791a","article-title":"INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma","volume":"4","author":"Seder","year":"2009","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-010-9766-y","article-title":"Upregulated INHBA expression is associated with poor survival in gastric cancer","volume":"29","author":"Wang","year":"2012","journal-title":"Med. Oncol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)00116-1","article-title":"Signal transduction by the JNK group of MAP kinases","volume":"103","author":"Davis","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.10.037_bib0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ceb.2007.02.001","article-title":"The JNK signal transduction pathway","volume":"19","author":"Weston","year":"2007","journal-title":"Curr. Opin. Cell Biol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0185","first-page":"863","article-title":"The expression of proto-oncogene c-jun in human pancreatic cancer","volume":"19","author":"Tessari","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canlet.2014.10.037_bib0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1124\/jpet.104.078873","article-title":"Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase","volume":"313","author":"Ennis","year":"2005","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.canlet.2014.10.037_bib0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/cas.12080","article-title":"Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer","volume":"104","author":"Takahashi","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.canlet.2014.10.037_bib0200","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.18632\/oncotarget.2087","article-title":"Targeting the K-Ras\u2013JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation","volume":"5","author":"Okada","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2014.10.037_bib0205","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.10.037_bib0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.canlet.2014.10.037_bib0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R","article-title":"Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas","volume":"21","author":"Ruggeri","year":"1998","journal-title":"Mol. Carcinog"},{"key":"10.1016\/j.canlet.2014.10.037_bib0225","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1073\/pnas.93.8.3636","article-title":"Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA","volume":"93","author":"Cheng","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2014.10.037_bib0230","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jcb.10287","article-title":"Frequent activation of AKT2 kinase in human pancreatic carcinomas","volume":"87","author":"Altomare","year":"2002","journal-title":"J. Cell. Biochem"},{"key":"10.1016\/j.canlet.2014.10.037_bib0235","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1152\/ajpcell.00105.2009","article-title":"Myostatin reduces Akt\/TORC1\/p70S6K signaling, inhibiting myoblast differentiation and myotube size","volume":"296","author":"Trendelenburg","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0240","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1152\/ajpcell.00104.2009","article-title":"Smad2 and 3 transcription factors control muscle mass in adulthood","volume":"296","author":"Sartori","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0245","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1152\/ajpcell.00114.2011","article-title":"Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins","volume":"301","author":"Lokireddy","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1016\/j.canlet.2014.10.037_bib0250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin. Exp. Metastasis"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351400648X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351400648X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T21:46:37Z","timestamp":1565991997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438351400648X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S030438351400648X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.10.037","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}